MPG.eBooks - Search Results

1

Nitisinone (Orfadin) (Sobi Canada Inc.)

Published 2018

CADTH

Subjects: “...Canada...”

Read Now

2

Pharmacoeconomic review report: Travoprost 0.003% (Izba) (Novartis Pharmaceuticals Canada Inc. on behalf of Icon Canada Inc.)

Published 2017

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Canada...”

Read Now

3

Clinical review report: Travoprost 0.003% (Izba) (Novartis Pharmaceuticals Canada Inc. on behalf of Icon Canada Inc.)

Published 2017

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Canada...”

Read Now

4

CADTH Canadian Drug Expert Committee recommendation: Brexpiprazole (Rexulti - Lundbeck Canada Inc...

Published 2017

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Canada...”

Read Now

5

Pharmacoeconomic review report: Travoprost 0.003% (Izba) (Novartis Pharmaceuticals Canada Inc. on behalf of Icon Canada Inc.)

Published 2017

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Canada...”

Read Now

6

Pharmacoeconomic review report: Brexpiprazole (Rexulti) : (Lundbeck Canada Inc. and Otsuka Canada Pharmaceutical Inc.) : indication: treatment of schizophrenia in adults

Published 2017

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Canada...”

Read Now

7

Clinical review report: Brexpiprazole (Rexulti) : (Lundbeck Canada Inc. and Otsuka Canada Pharmaceutical Inc.) : indication: treatment of schizophrenia in adults

Published 2017

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Canada...”

Read Now

8

Clinical review report: Brexpiprazole (Rexulti) : (Lundbeck Canada Inc. and Otsuka Canada Pharmaceutical Inc.) : indication: treatment of schizophrenia in adults

Published 2017

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Canada...”

Read Now

9

Patient group input submissions: Brexpiprazole (Rexulti) (Lundbeck Canada Inc. and Otsuka Canada...

Published 2017

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Canada...”

Read Now

10

Pharmacoeconomic review report: Von Willebrand factor (Recombinant) (Vonvendi) (Shire Pharma Canada...

Published 2021

Canadian Agency for Drugs and Technologies in Health

“...Von Willebrand factor (Recombinant) (Vonvendi) (Shire Pharma Canada ULC, now part of Takeda Canada...”

Read Now

11

CADTH Canadian Drug Expert Committee recommendation: Travoprost 0.003% (Izba -- Novartis Pharmaceuticals Canada inc. on behalf of Alcon Canada Inc.)...

Published 2017

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Canada...”

Read Now

12

Clinical review report: Letermovir (Prevymis) (Merck Canada Inc.)

Published 2018

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Canada...”

Read Now

13

Pharmacoeconomic review report: Letermovir (Prevymis) (Merck Canada Inc.)

Published 2018

CADTH

Subjects: “...Canada...”

Read Now

14

Clinical review report: Nusinersen (Spinraza) (Biogen Canada Inc.)

Published 2018

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Canada...”

Read Now

15

Clinical review report: Doravirine (Pifeltro) (Merck Canada Inc.)...

Published 2019

CADTH

Subjects: “...Canada...”

Read Now

16

Clinical review report: Efinaconazole (Jublia) (Valeant Canada LP)

Published 2019

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Canada...”

Read Now

17

Pharmacoeconomic review report: Efinaconazole (Jublia) (Valeant Canada LP)

Published 2019

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Canada...”

Read Now

18

Pharmacoeconomic report: Ofatumumab (Kesimpta) (Novartis Pharmaceuticals Canada Inc.) : indication: multiple sclerosis, relapsing-remitting

Published 2021

Canadian Agency for Drugs and Technologies in Health

“...Ofatumumab (Kesimpta) (Novartis Pharmaceuticals Canada Inc.)...”

Read Now

19

Clinical review report: Tofacinitib (Xeljanz) (Pfizer Canada inc.)...

Published 2019

Canadian Agency for Drugs and Technologies in Health

“...Tofacinitib (Xeljanz) (Pfizer Canada inc.)...”

Read Now

20

Clinical review report: Letermovir (Prevymis) (Merck Canada Inc.)

Published 2018

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Canada...”

Narrow Search